

Alkem launches anti-seizure drug NeuCeno in India

The once-daily drug branded as NeuCeno, will be available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg strengths.



New Delhi: Mumbai-based Alkem Laboratories announced the launch of cenobamate, an anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients.

The once-daily drug branded as NeuCeno, helps to calm overactive brain cells. It works by reducing the electrical signals that make brain cells fire repeatedly and enhances brain's natural inhibitory signals by modulation of GABA-A receptors, the protein channels in the brain that calm down nerve activity when triggered by the main relaxing chemical, gamma-aminobutyric acid (GABA).

Under trials, it adults with uncontrolled focal seizures on existing anti-seizure medications,, the NeuCeno demonstrated up to 78 per cent reduction in seizure frequency and up to 30 per cent patients achieved seizure freedom during the maintenance phase.

Alkem will market the oral pill, in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg strengths. The company did not disclose the drug's market price.

“People living with epilepsy face significant challenges in achieving effective seizure control. Cenobamate has the potential to improve outcomes towards delivering better management,” said Sandeep Singh, MD, Alkem Laboratories.

Alkem shares closed at Rs 5,188 up 0.66 per cent, apiece on the BSE.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/alkem-launches-anti-seizure-drug-neuceno-in-india/134284077>